Stem Cell Pancreatic Endocrine Differentiation for β-Cell Supply
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The scarcity and quality of donor islets limit the effectiveness of β-cell transplantation therapy for diabetes, necessitating the development of a method to generate an unlimited supply of functional human β-cells from stem cells.
Innovation Solution
A multi-step differentiation process involving the use of specific signaling pathway modulators and growth factors to convert PDX1-positive, NKX6.1-negative pancreatic progenitor cells into PDX1-positive, NKX6.1-positive pancreatic progenitor cells, and subsequently into NKX6.1-positive, ISL1-positive endocrine cells, with controlled expression profiles of markers such as C-peptide, glucagon, and somatostatin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cadaveric human islets are used for transplantation, then patients can be made insulin independent for 5 years or longer, but the scarcity and quality of donor islets limits the therapy
Solution Approach 1:
The patent creates copies of functional β-cells by differentiating human pluripotent stem cells into pancreatic progenitor cells and then into mature β-cells. This copying process generates unlimited supplies of functional islet cells that can be transplanted, replacing the need for scarce donor islets while maintaining the therapeutic effectiveness of 5+ years insulin independence
Solution Approach 2:
The patent employs systematic parameter changes in the differentiation process by modulating signaling pathways (TGF-β, Wnt, Notch, BMP) and adjusting growth factor concentrations at different stages. This controlled parameter manipulation transforms pluripotent stem cells through intermediate pancreatic progenitor stages to mature β-cells, enabling scalable production of high-quality islet cells that match donor islet functionality
2Productivity
If a multi-step differentiation process is used to generate β-cells from stem cells, then an unlimited supply of human β-cells can be produced, but the process complexity increases
Solution Approach 1:
The patent segments the β-cell differentiation process into distinct sequential stages: (1) pluripotent stem cell maintenance, (2) definitive endoderm formation, (3) pancreatic progenitor cell generation, (4) endocrine cell differentiation, and (5) mature β-cell maturation. Each stage employs specific signaling pathway modulators and growth factors, allowing systematic control and optimization of each step while enabling scalable production
Solution Approach 2:
The patent applies preliminary actions by pre-establishing optimal culture conditions and signaling pathway modulation protocols for each differentiation stage before initiating the process. Growth factors and pathway inhibitors/activators are prepared and applied in predetermined sequences, streamlining the complex multi-step process and enabling reproducible large-scale β-cell production
Data Source
AI summary
Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic endocrine cells. In some aspects, the methods provided herein relate to generation of pancreatic β cell, α cell, δ cells, and EC cells in vitro. In some aspects, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.